Excision BioTherapeutics Inc.
3624 Market St, Office# 514
Philadelphia
Pennsylvania
19104
United States
Website: http://www.excisionbio.com/
Email: info@excisionbio.com
33 articles with Excision BioTherapeutics Inc.
-
Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting
5/17/2022
Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that preclinical and bioinformatic data showing robust and specific editing of HIV proviral DNA with EBT-101 will be featured in an upcoming poster presentation at ASGCT.
-
Revealed in an article published in Science magazine, this new variant of HIV was discovered in individuals in the Netherlands, Belgium and Switzerland.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Moderna invested heavily in mRNA technology to manufacture some 900 million doses of the COVID-19 vaccine. Now, the company has created an mRNA-based vaccine to prevent HIV.
-
Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
1/27/2022
Excision BioTherapeutics, Inc. today announced the initiation of a first-in-human (FIH) Phase 1/2 clinical trial of EBT-101 in individuals living with human immunodeficiency virus type 1 (HIV).
-
Exavir Therapeutics announced that it was able to eliminate HIV from human cells with lipid nanoparticle (LNP)-delivered Tat-targeted CRISPR-Cas9.
-
Excision BioTherapeutics Expands Management Team with Three Key Appointments
10/12/2021
Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced the expansion of its management team with the appointments of Sara Turken, J.D., as General Counsel, Manish Anand, M.Sc., as Senior Vice President, Regulatory Affairs, and Robert Gunning, CPA, CGMA, as VP, Controller.
-
The FDA's IND approval sets the stage for the very first Phase I/II trial to evaluate EBT-101 as a functional cure for chronic HIV based on the endpoints of safety, tolerability, and efficacy.
-
Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
9/15/2021
Excision BioTherapeutics, Inc., the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for EBT-101, a CRISPR-based therapeutic candidate in development as a potential functional cure for chronic HIV.
-
Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
8/26/2021
Excision BioTherapeutics Inc announced that the Temple University team collaborating with Excision on a project, CRISPR for Cure, has received a Martin Delaney Grant from the National Institutes of Health of $4.8 million on an annual basis for the next five years as a part of approximately $53 million annual funding from the NIH to find a cure for HIV.
-
BioSpace Movers & Shakers, July 30, 2021
7/30/2021
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers. -
Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer
7/29/2021
Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of Lisa Danzig, M.D., as Chief Medical Officer.
-
BioSpace Movers & Shakers, May 28
5/28/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine
5/27/2021
Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of infectious disease expert and clinical scientist Sumathi Sivapalasingam, M.D., as Head of Translational Medicine.
-
Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing
5/24/2021
Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry development veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing.
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board
5/5/2021
Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of gene therapy and rare disease expert, Nicole Paulk, Ph.D., to its Scientific Advisory Board (SAB).
-
Excision BioTherapeutics Appoints Seasoned Finance Executive Christine Silverstein as Chief Financial Officer
5/3/2021
Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of Christine Silverstein as Chief Financial Officer.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical Development
4/1/2021
Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry research and development veteran, William Kennedy, M.D., as Senior Vice President, Clinical, effective Thursday, April 1.